SCHEMBL2675765

SCHEMBL2675765

O=c1[nH]c(-c2ccc(S(=O)(=O)N3CCc4cc(-c5ccc(C(F)(F)F)cc5)ccc43)c(-c3ccc(C(F)(F)F)cc3)c2)no1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 5/20 0.45
CNR1 P21554 1/20 0.42
MAPT P10636 4/20 0.40
CYP11B2 P19099 3/20 0.40
RORC P51449 1/20 0.38
NR1H3 Q13133 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
NR1I2 O75469 1/20 0.37
BRS3 P32247 1/20 0.37
TYK2 P29597 1/20 0.36
S1PR1 P21453 1/20 0.36
RARB P10826 1/20 0.35
KIF11 P52732 1/20 0.35
KDM2B Q8NHM5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2674505 0.90 CYP11B1 (0.44) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL2675371 0.88 CYP11B1 (0.55) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL1396180 0.84 CYP11B1 (0.47) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL2675306 0.83 CYP11B1 (0.47) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL1396289 0.82 CYP11B1 (0.50) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL1396272 0.82 CYP11B1 (0.44) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL1396279 0.78 CYP11B1 (0.48) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL1396322 0.78 CYP11B1 (0.49) CYP11B1MAPTCYP11B2RORCNR1H3
SCHEMBL2675836 0.77 MAPT (0.44) CYP11B1CNR1MAPTCYP11B2RORC
SCHEMBL14161101 0.75 CYP11B1 (0.38) CYP11B1CNR1MAPTCYP11B2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US claimed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US claimed
EP-2102198-B1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2015-02-25 EP disclosed
EP-2102198-B1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2015-02-25 EP disclosed
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US disclosed
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US disclosed
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
EP-2102198-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-23 EP disclosed
WO-2008071311-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-06-19 WO disclosed
WO-2008071311-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS PPARD, PPARG, PPARA CYP11B1 89/4885CNR1 332/4885MAPT 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.